Outset Medical Appoints Renee Gaeta as CFO

The latest announcement is out from Outset Medical ( (OM) ).

On June 3, 2025, Outset Medical announced the appointment of Renee Gaeta as Chief Financial Officer, succeeding Nabeel Ahmed. Gaeta brings extensive financial leadership experience from her previous roles at various medical technology companies. Her appointment is expected to support Outset’s growth and profitability goals. The company also reiterated its 2025 financial guidance, projecting revenues between $115 million and $125 million, with a non-GAAP gross margin in the high-30% range. Additionally, Outset held its Annual Meeting of Stockholders on June 2, 2025, where key proposals, including amendments to equity and stock purchase plans, were approved.

The most recent analyst rating on (OM) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Outset Medical stock, see the OM Stock Forecast page.

Spark’s Take on OM Stock

According to Spark, TipRanks’ AI Analyst, OM is a Neutral.

Outset Medical’s stock is moderately rated due to positive technical momentum and promising earnings call insights, tempered by significant financial challenges and valuation concerns. The company needs substantial operational improvements to achieve profitability and sustainable growth.

To see Spark’s full report on OM stock, click here.

More about Outset Medical

Outset Medical, Inc. is a medical technology company that has developed the Tablo Hemodialysis System, a first-of-its-kind technology designed to reduce the cost and complexity of dialysis. The system is FDA cleared for use from the hospital to the home, offering a comprehensive solution that simplifies dialysis for providers and transforms the experience for patients. Tablo integrates water purification and on-demand dialysate production, enabling it to function as a mobile dialysis clinic with advanced data analytics capabilities.

Average Trading Volume: 169,183

Technical Sentiment Signal: Sell

Current Market Cap: $315.3M

See more data about OM stock on TipRanks’ Stock Analysis page.